Alcon Inc. (SWX:ALC)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
75.36
+1.24 (1.67%)
Apr 15, 2025, 5:19 PM CET
1.59%
Market Cap 36.66B
Revenue (ttm) 8.98B
Net Income (ttm) 922.49M
Shares Out 494.62M
EPS (ttm) 1.86
PE Ratio 39.90
Forward PE 28.13
Dividend 0.28 (0.38%)
Ex-Dividend Date May 13, 2025
Volume 651,647
Average Volume 1,365,672
Open 74.62
Previous Close 74.12
Day's Range 74.54 - 75.64
52-Week Range 67.34 - 87.00
Beta 0.77
RSI 45.01
Earnings Date May 14, 2025

About Alcon

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]

Sector Healthcare
Founded 1945
Employees 25,599
Stock Exchange SIX Swiss Exchange
Ticker Symbol ALC
Full Company Profile

Financial Performance

In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.

Financial numbers in USD Financial Statements

News

Alcon proposes CHF 0.28 dividend

4 days ago - Seeking Alpha

Alcon: A Clear Vision, But Fully Valued

5 days ago - Seeking Alpha

Alcon Inc (ALC) Announces Upcoming Annual General Meeting and Board Changes

Alcon Inc (ALC) Announces Upcoming Annual General Meeting and Board Changes

11 days ago - GuruFocus

Alcon Publishes Agenda for 2025 Annual General Meeting

GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.

11 days ago - Business Wire

Alcon Publishes Agenda for 2025 Annual General Meeting

GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.

11 days ago - Business Wire

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

GENEVA--(BUSINESS WIRE)--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter.

13 days ago - Business Wire

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease.

19 days ago - Business Wire

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...

20 days ago - Business Wire

Alcon Stock Sees RS Rating Climb To 74

A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?

20 days ago - Investor's Business Daily

Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe

Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe

21 days ago - GuruFocus

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.

21 days ago - Business Wire

Alcon Eyes Surgical Edge With LENSAR Buyout: Details

Alcon is set to acquire LENSAR Inc. in a ... Full story available on Benzinga.com

22 days ago - Benzinga

Alcon Agrees to Acquire LENSAR, Inc.

GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.

22 days ago - Business Wire

Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offerin...

22 days ago - GlobeNewsWire

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

4 weeks ago - Business Wire

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

4 weeks ago - Business Wire

Alcon Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?

5 weeks ago - Investor's Business Daily

Alcon Inc (ALC) Expands TOTAL30® for Astigmatism Contact Lens Parameters

Alcon Inc (ALC) Expands TOTAL30® for Astigmatism Contact Lens Parameters

6 weeks ago - GuruFocus

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Ast...

6 weeks ago - Business Wire

Watch CNBC's full interview with Alcon CEO David Endicott

Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.

6 weeks ago - CNBC International TV